The ferocious bear mauling of Anavex Life Sciences Corp. AVXL shares has left investors shaking in their boots. The company reported a disheartening fourth-quarter financial loss, with shares plummeting a staggering 10% to $6.35 on Monday.
The company’s dismal performance revealed a quarterly net loss of $10.1 million, including a brutal $3.2 million in non-cash items, translating to a harrowing 12 cents per share for the fourth quarter. This was a wipeout from a year-ago net loss of $14.3 million, inclusive of $6.0 million in non-cash items, or 18 cents per share during the year-ago period.
Meanwhile, in a show of solidarity, other stocks are also weathering the storm, thus demonstrating that to the brave go the spoils. Here’s a rundown of the most ferocious gainers and how they managed to evade the bear’s clutches:
- RedHill Biopharma Ltd. RDHL shares carved out a heroic climb of 125% to $0.7063 after the company announced the FDA has granted five years’ market exclusivity for Talicia.
- Biodexa Pharmaceuticals Plc BDRX bravely gained 122.8% to $5.96 after securing an exclusive worldwide license to tolimidone.
- 10X Capital Venture Acquisition Corp. II VCXA shares valiantly dipped 21.2% to $8.39, displaying resilience even in the face of misfortune.
Investors are advised to tread carefully as they navigate these treacherous market waters, where only the most unwavering stocks will emerge triumphant.